Substituted Lactams for Glaucoma Treatment via Aqueous Humor Outflow
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma, particularly primary and secondary glaucoma, face challenges in effectively reducing intraocular pressure due to obstruction of aqueous humor outflow, and existing medications may not adequately address the underlying causes of increased intraocular tension.
Innovation Solution
Development of specific compounds, including (R)-2-(2-(1-(4-(1-hydroxyhexyl)phenyl)-5-oxopyrrolidin-2-yl)ethylthio)thiazole-4-carboxylic acid and its derivatives, which are administered to reduce intraocular pressure and treat glaucoma by improving aqueous humor outflow.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional topical β-adrenoreceptor antagonists are used to treat glaucoma, then intraocular pressure reduction is achieved, but the underlying cause of increased intraocular tension due to obstruction of aqueous humor outflow is not adequately addressed
Solution Approach 1:
The patent modifies the molecular structure of lactams by changing chemical parameters (introducing specific substituents at defined positions) to create compounds that simultaneously achieve intraocular pressure reduction and address the underlying obstruction mechanism. The structural modifications enable the compounds to interact with multiple pathways involved in aqueous humor outflow obstruction.
Solution Approach 2:
The invention creates composite therapeutic agents by combining the lactam core structure with specific side chains and substituents (such as aryl groups, heteroaryl groups, and various functional moieties). This composite molecular design allows the single compound to perform multiple functions: reducing intraocular pressure while also addressing the underlying causes of glaucoma through multi-target activity.
2Productivity
If existing medications are used to manage glaucoma, then intraocular pressure is reduced to some extent, but the obstruction of aqueous humor outflow remains insufficiently addressed
Solution Approach 1:
The patent segments the molecular structure into distinct functional regions: a core lactam ring system and various substituent groups (aryl, heteroaryl, alkyl, etc.) attached at specific positions. This segmentation allows each region to be optimized for specific biological activities, with the core providing structural stability and the substituents providing specific interactions with targets involved in aqueous humor outflow obstruction.
Solution Approach 2:
The invention introduces dynamic molecular features including chiral centers (specified as (R)-configuration in the patent), double bonds with specific configurations (E/Z), and flexible side chains that can adapt to different binding sites. These dynamic elements enable the compound to effectively interact with multiple targets in the aqueous humor outflow pathway, improving both the rate and reliability of pressure reduction.
Data Source
AI summary
Therapeutic compounds, compositions, medicaments, and methods are disclosed herein.